Solid underlying growth for Astellas in first quarter
This article was originally published in Scrip
Like many of its Japanese peers, Astellas suffered from the strength of the yen in the first quarter to June 30th. Currency effects knocked ¥16.8 billion off its sales, which came in 1% lower at ¥252.1 billion ($2.65 billion).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.